Case Report: TPR-ALK fusion-positive inflammatory myofibroblastic tumour treated with sequential ALK inhibitors

This case highlights the importance of comprehensive molecular testing in IMT to identify actionable <i>ALK</i> fusions and supports the use of sequential <i>ALK</i> inhibitor therapy. This <i>TPR-ALK</i> fusion-driven IMT demonstrates that disease progression after an initial response to crizotinib can be effectively overcome with lorlatinib, resulting in rapid and durable clinical benefit. These findings add to emerging evidence supporting next-generation <i>ALK</i> inhibitors as effective treatment options for <i>ALK</i>-rearranged IMT after crizotinib failure.